In February 2021 Tavistock helped make history as PR advisor to MGC Pharmaceuticals, the first medicinal cannabis company to IPO on the London Stock Exchange, which raised £6.5m in the process.
MGC Pharma is a European based bio-pharma company developing and supplying affordable standardised phyto-medicines to patients globally. It’s research and treatments are focused on using phytomedicines in three core areas: Neurology, Oncology, and Autoimmune diseases – including ArtemiC™ for treatment of Covid-19 infected patients.
Tavistock was hired by Rolls Royce to assist on its communications for its Small Modular Reactor technology (SMR). The brief was put out to competitive tender to design a campaign for SMRs to respond to a £250m UK Government research grant programme.
Tavistock advised the Board of Dee Valley Water on Severn Trent's £84 million takeover bid.
Tavistock advised the Board of Gemfields plc during its £220m hostile takeover.
Tavistock advised Ten Lifestyle Group plc on its IPO onto the AIM Market of the London Stock Exchange.
Tavistock advised Resolute on its 2019 dual listing on the London Stock Exchange.